Update on Lung Cancer Image Processing Rick Avila Karthik Krishnan Luis Ibanez Kitware, Inc. April 19, 2006.

Slides:



Advertisements
Similar presentations
Parameters and Trade-offs
Advertisements

INTRODUCTION ABOUT OMR. INDEX  Concept/Definition  Form Design  Scanners & Software  Storage  Accuracy  OMR Advantages  Commercial Suppliers.
Automatic Segmentation and Volume Estimation of Lung Cancer Nodules using Computed Tomography Timothy R. Tuinstra, PhD Candidate.
Multi trial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse Background:
The Need for Quantitative Imaging in Oncology Richard L. Schilsky, M.D. Professor of Medicine, Associate Dean for Clinical Research, University of Chicago.
IMAGE QUALITY NOISE LINEARITY CROSS-FIELD UNIFORMITY IMAGE ARTIFACTS.
Volumetric Measurement of Tumors David F. Yankelevitz, MD.
Response Assessment Criteria for Clinical Trials Tumor Imaging Metrics Core January 29, 2008 Cheryl A. Sadow, MD Abdominal Imaging & Intervention Division.
15 February Partial volume correction for liver metastases and lymph nodes1Institute for Medical Image Computing/16SPIE 2010 Partial volume correction.
lecture 4 : Isosurface Extraction
1 Research Update/Review LAE 5/23/08. 2 RIN/Recurrent Disease: The Problem T1 weighted contrast enhanced MRI taken 16 months after completion of radiotherapy.
Yujun Guo Kent State University August PRESENTATION A Binarization Approach for CT-MR Registration Using Normalized Mutual Information.
McDaniels – Feb 29, Outline Patient 6 question Patient 11 ADC results Abstract for AAPM conference.
ISSSMA June 3 rd Advanced quantification in oncology PET Irène Buvat IMNC – UMR 8165 CNRS – Paris 11 University Orsay, France
CT Quality Control for CT Scanners. Quality Control in CT A good idea? Yes Required for accreditation? Sometimes Improves image quality? Sometimes Depends.
QIBA CT Volumetrics - Cross-Platform Study (Group 1C) May 6, 2009 Interclinic Comparison of CT Volumetry Quantitative Imaging Biomarker Alliance.
Tumor Measurement Criteria milestones & 2000
Sketch-Based Interactive Segmentation and Segmentation Editing for Oncological Therapy Monitoring Frank Heckel March 17, 2015 BVM-Award 2015 – PhD Thesis.
Attenuation of Treatment Effect Due to Measurement Variability in Assessment of Progression-Free Survival Pharmaceut. Statist. 2012, –402 Nicola.
QIBA CT Volumetrics - Cross-Platform Study (Group 1C) December 23, 2009 CT Cross-platform Sizing of Phantom Lesions Quantitative Imaging Biomarker Alliance.
Imaging Workspace An Overview and Roadmap Eliot L. Siegel, MD Imaging Workspace Lead SME January 23, 2008.
Slide - 1 Confidential. Slide - 2 Confidential Slide - 3 Confidential Interalgorithm Study using CT Images of synthetic nodules……….
COMBI RECIST 1.1 February Target Lesions: Selection at Baseline Perform baseline evaluations as close to treatment start as possible (no more than.
RECIST Overview.
Immune Related Response Criteria (irRC) Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors Training Presentation v3.0.
S Demehri 1, M.K Kalra 2, M.L Steigner 1, F.J Rybicki 1, M.J. Lang, 3, S.G Silverman 1. 1.Department of Radiology, Brigham & Women's Hospital, Harvard.
QIBA CT Volumetrics - Cross-Platform Study (Group 1C) September 2, 2009 Interclinical Comparison of CT Volumetry Quantitative Imaging Biomarker Alliance.
Anatomic and Functional Imaging Evaluation of a Clinical Trial of an IGFR Antibody in Patients (PTS) with Ewing Sarcoma (ES) Vadim Koshkin; Vanessa Bolejack;
MEDICAL IMAGE ANALYSIS Marek Brejl Vital Images, Inc.
Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation J Nucl Med 2003; 44:1225–1231 Intern 魏敬庭.
QIBA CT Volumetrics Group 1B: (Patient Image Datasets) Update April 19, 2011.
QIBA CT Volumetrics Group 1B: (Patient Image Datasets)
Copyright © 2010 Siemens Medical Solutions USA, Inc. All rights reserved. Hierarchical Segmentation and Identification of Thoracic Vertebra Using Learning-based.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
QIBA CT Volumetrics - Cross-Platform Study (Group 1C) March 18, 2009 Interclinic Comparison of CT Volumetry Quantitative Imaging Biomarker Alliance.
Focal Analysis of Knee Articular Cartilage Quantity and Quality Dr. Tomos G. Williams Imaging Science and Biomedical Engineering University of Manchester.
QIBA CT Volumetrics Group 1B: (Patient Image Datasets) Teleconference Nov 5, 2008.
3D sequence MRI in the assessment of meniscofemoral and ligament lesions of the knee MA.Chaabouni,A.Daghfous, A.Ben Othman,L.Rezgui Marhoul Radiology departement.
Limitations of RECIST guidelines Srinivasa R Prasad MD Associate Professor, Radiology University of Texas Health Science Center at San Antonio.
Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer
Part No...., Module No....Lesson No
A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.
1 A continued FDA Concern about Imaging Based Drug Trials Society of Nuclear Medicine Albuquerque, Feb 1-2, 2009 Orhan H Suleiman MS PhD, FAAPM Senior.
Quality Control Bushong Chapter 10.
Federating Standardized Clinical Brain Images Across Hospitals.
Imaging Workspace An Overview and Roadmap Eliot L. Siegel, MD Imaging Workspace Lead SME January 23, 2008.
Submitted by :- Sridev Shyam K.V. Problem Definition.
Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Selumetinib vs Chemotherapy on Progression-Free.
Automatic Lung Nodule Detection Using Deep Learning
IMAGE QUALITY. SPATIAL RESOLUTION CONTRAST RESOLUTION NOISE IMAGE ARTIFACTS RADIATION DOSE.
Team Plan/Expected Challenges
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Audit Update LUNG-MAP Rose Ermete, Rn, bsn, ocn, ccrp
Compositional Human Pose Regression
Two lesions are seen within the lateral segment of the left lobe of the liver (yellow arrows). They appear mildly hyperintense on T2 images and mildly.
Dose-escalation patient response.
CS 698 | Current Topics in Data Science
Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion
Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Rep Oncol 2016;9:
A, baseline and 4-week PET scan from patient 2 (MET c
Volume 65, Issue 4, Pages (April 2014)
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.
Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.
Computed Tomography (C.T)
Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.
A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.
Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.
Survival, subsequent therapies, and response.
Presentation transcript:

Update on Lung Cancer Image Processing Rick Avila Karthik Krishnan Luis Ibanez Kitware, Inc. April 19, 2006

Kitware Therapy Assessment Start Therapy Time Assessment Tumor responseTumor response ID new lesionsID new lesions ? Tumor Size tttt Assess Response 4 cm lesion Characteristics Late stageLate stage Thick CTThick CT ?

Kitware RECIST Time Baseline & Treat Assess Response  D = -30%  D = +20% Stable Disease Partial Response Complete Response Progressive Disease weeks Target Lesion Measurement RECIST: Sum of LD Unaided Interpretation 4cm lesion 8mm  D, 13 pixels 73%  Volume Erasmus et. al., JCO 2003 Intra-observer error PD: 9.5% of tumors PR: 3% of tumors Inter-observer error PD: 30% of tumors PR: 14% of tumors Erasmus et. al., JCO 2003 Intra-observer error PD: 9.5% of tumors PR: 3% of tumors Inter-observer error PD: 30% of tumors PR: 14% of tumors

Kitware We can do better Time Stable Disease Partial Response Complete Response Progressive Disease tt Target Lesion Measurement RECIST: Sum of LD Aided 3D Interpretatio n Improve: BiasBias VarianceVariance For Lower: Interval (  t)Interval (  t) Study NStudy N Early Detection & Nodule Sizing? 4cm lesion

Kitware First Step: Open Development Databases All Cases Shown In This Presentation Came From These Databases

Kitware Measurement Challenges Patient/Lesion Presentation –Size –Complexity –Changes over time (necrosis) Scanners –Hardware –Software Protocols –ScanRx –Contrast –Patient position Observer –Seed points/ROI –Data Interpretation 5mm 2.5mm

Kitware Complex Boundaries

Kitware

Kitware Volumetric Algorithm Challenges Boundary Identification Challenges Vascular network (Ev)Vascular network (Ev) Bronchial network (Eb)Bronchial network (Eb) Pleura (Ep)Pleura (Ep) Sub-voxel edge (Es)Sub-voxel edge (Es) Errors at 2 time points Ev Error strongly depends on lesion size and slice thickness Ep Pleura Es No/Small  I

Kitware Solid Algorithm: Operating Envelope Lesion Size Slice Thickness 10mm20mm 15mm 5mm mm 2.5 mm 3.75 mm 5.0 mm ComplexBoundaries PartialVolume Noise… Curvature… ClinicalTrials Solution <= 1.25mm thickness<= 1.25mm thickness Algorithm support for complex intersectionsAlgorithm support for complex intersections Validate against wide patient and protocol populationValidate against wide patient and protocol population

Kitware Motivating Example 46d 69d 59mm48mm44mm 1D  25% RECIST would classify response to therapy as Stable Disease

Kitware 3D Analysis

Kitware

Kitware Validation Approach Time Baseline & Treat Stable Disease Partial Response Complete Response Progressive Disease Response Metric Case Collection Collect cases w/many short interval scansCollect cases w/many short interval scans Assessment on last scan(s) is clearAssessment on last scan(s) is clear Annotation One or more expert(s) classify each case based on all dataOne or more expert(s) classify each case based on all data T1T2T3T4T5 Metric Measure sens/spec between assess pairsMeasure sens/spec between assess pairs Compare metrics at last time pointCompare metrics at last time point At what time can a sens/spec be met?At what time can a sens/spec be met?

Kitware Open Database Collection Priorities Add Annotation to Open Databases –Need to assess RECIST as the baseline performance –Need an expert assessment of response for case Add More Cases to Open Databases –Wide range of patient/lesion presentations –Wide range of therapy interactions Emphasize Thin Slice –Algorithms perform better (e.g. I’’) Collect Data at Smaller Time Intervals –Algorithms perform better (e.g. registration)

Thank You

Kitware Edge Detection Algorithms that utilize acquisition characteristics (e.g. PSF, SNR) can adapt to changes in acquisition Step Function PSF + Noise ObjectScannerImage SmoothLocalize Recover Edge Using Acquisition Characteristics Elder et. al. TPAMI 1998

Kitware Cross-Platform Capability Goal:Goal: –Software achieves accuracy despite variation in: Scanning equipmentScanning equipment Acquisition protocolsAcquisition protocols Solution:Solution: –Establish minimum acquisition standards/protocols –Keep acquisition technique constant per patient –Measure scanner characteristics utilizing a standard phantom and publish –Utilize model-based algorithms

Kitware Unexpected Results Many studies report greater variance and error when comparing 1D/2D/3D analysis –Issue 1: More is not always better All measurements need high precisionAll measurements need high precision Consider slice thicknessConsider slice thickness –Issue 2: New metrics need optimization Development data needed to establish best separation between response classesDevelopment data needed to establish best separation between response classes